What's next for dyslipidemia management? the 2013 ACC/AHA Guidelines, the NLA recommendations, and beyond

Journal of the American Pharmacists Association

Volumn 56, Issue 3, 2016, Pages 284-292

  Waite, Laura H ^a   Phan, Yvonne L ^a   Spinler, Sarah A ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; DRUG APPROVAL; DYSLIPIDEMIA; EDUCATION PROGRAM; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HUMAN; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; AGING; COMBINATION DRUG THERAPY; COMORBIDITY; DYSLIPIDEMIAS; HEALTH BEHAVIOR; LIFESTYLE; MEDICAL SOCIETY; UNITED STATES;

AGING; COMORBIDITY; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HEALTH BEHAVIOR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIFE STYLE; PRACTICE GUIDELINES AS TOPIC; RISK ASSESSMENT; RISK FACTORS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 84969253441     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1016/j.japh.2015.12.017     Document Type: Review

References (13)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S1-S45.
3. McKenney JM. Something important is missing in the ACC/AHA cholesterol treatment guidelines. J Am Pharm Assoc. 2015;55(3): 324-329.
4. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient centered management of dyslipidemia: part 1-executive summary. J Clin Lipidol. 2014;8(5):473-488.
5. Jacobson TA, Maki KC, Orringer C, et al. National Lipid Association recommendations for patient centered management of dyslipidemia: part 2. J Clin Lipidol. 2015;9(6 suppl):S1-S122.e1.
6. Cannon CP, Blazing MA, Guigliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndrome (IMPROVE-IT). N Engl J Med. 2015;372(25):387-397.
7. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16): 1489-1499.
8. Koren MJ, Lundqvist P, Bolognese M, et al. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol. 2014;63(23):2531-2540.
9. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evo-locumab in reducing lipids and cardiovascular events. N Engl J Med. 2015;372(16):1500-1509.
10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo controlled trial of evolocumab in hyperlipidemia. N Engl J Med. 2014;370(19):1809-1819.
11. Raal FJ, Stein EA, Dufour R, et al, RUTHERFORD-2 investigators. PCSK9 inhibition with evolocumab (A MG 145) in heterozygous familial hy-percholesterolemia: a randomized, double-blind, placebo-controlled trial. Lancet. 2015;385(9965):331-340.
12. McKenney JM, Davidson MH, Jacobson TA, Guyton JR. National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol. 2006;97(8A):89C-94C.
13. Jacobson TA. NLA Task Force on statin safetye2014 update. J Clin Lipidol. 2014;8(3 suppl):S1-S4.